Congress bans NIH funding for animal research abroad, redirecting billions to U.S. labs

What it does

This bill prohibits the National Institutes of Health from funding animal research conducted outside the United States. It cites $2.2 billion in NIH funding to foreign organizations for animal research from 2011–2021 and argues that foreign organizations self-report animal welfare without NIH inspection, creating risk of mistreatment. The bill redirects all future NIH animal-research funding to domestic U.S. locations only.

Why we flagged it

The bill's operative mechanism is a geographic restriction on NIH funding for animal research—a domestic-only requirement. It is framed as animal-welfare protection but functions as a funding-location mandate that redirects research spending from foreign to U.S. institutions.

What the text implies

• Domestic research institutions will face increased demand and may raise fees; NIH's animal-research budget may need to expand to maintain research volume at higher U.S. labor and facility costs.
• Foreign research collaborations involving animals will cease or be restructured; this may reduce U.S. participation in international research consortia and slow comparative studies.
• The bill assumes U.S. regulatory oversight (USDA, IACUC) is superior to foreign self-reporting, but does not fund enhanced inspection or enforcement—compliance burden falls on NIH and institutions.
• Research projects already underway in foreign locations may face mid-stream funding termination or forced relocation, creating disruption and potential waste of prior investment.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill protects animals from potential mistreatment by requiring NIH-funded research to occur under U.S. regulatory oversight, a public benefit. However, it may increase research costs (domestic labor and facilities are more expensive), potentially slowing medical progress or raising costs for U.S. taxpayers and patients; the net effect on human health outcomes is unclear and depends on whether domestic research can substitute efficiently for foreign work.

Who stands to gain

• U.S. research institutions (universities, medical centers, contract research organizations)
• U.S. laboratory animal suppliers and facility operators

Named in the bill

National Institutes of Health (NIH), Public Health Service Act, Section 495, USDA (implied regulatory authority), IACUC (Institutional Animal Care and Use Committees)

Where it stands

29 cosponsors: 21 Republicans, 8 Democrats.

• Feb 6, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 6, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $114,556 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Troy Nehls, the sponsor, reported $202,300 in PAC receipts in the 2026 cycle.

• Physicians Committee for Responsible Medicine — $114,556 on 2 filings

Lobbying Disclosure Act filings through Jul 16, 2026. A filing shows who paid to lobby on a bill it names, not what changed.